CIK 0001479419
- Non-accelerated filer
- Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270604595
- Phone
- +1 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- 4 Open-market sale SEE REMARKS sold 5,251 shares at $4.01 ($21,057)
- 4 Open-market sale Director sold 13,227 shares at $4.01 ($53,040)
- 4 Grant or award Director acquired 2,450 shares (grant or award)
- 4 Grant or award Director acquired 2,450 shares (grant or award)
- 4 Grant or award Director acquired 2,450 shares (grant or award)
- 4 Grant or award Director acquired 2,450 shares (grant or award)
- 4 Grant or award Director acquired 2,450 shares (grant or award)
- 4 Grant or award Director acquired 3,050 shares (grant or award)
- 4/A Open-market sale Director sold 10,866 shares at $3.74 ($40,639)
- 4 Open-market sale CHIEF BUSINESS OFFICER sold 730 shares at $3.74 ($2,730)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 2,850 shares at $3.74 ($10,659)
- 4 Open-market sale SEE REMARKS sold 3,390 shares at $3.74 ($12,679)
- 4 Open-market sale SEE REMARKS sold 3,687 shares at $3.74 ($13,789)
- 4 Open-market sale Director sold 10,866 shares at $3.74 ($40,639)
- 4 Derivatives Options or other derivatives
- 4/A Insider Changes in Ownership
- 4 Open-market sale CHIEF BUSINESS OFFICER sold 2,021 shares at $7.63 ($15,420)
- 4 Open-market sale SEE REMARKS sold 1,993 shares at $7.63 ($15,207)
- 4 Open-market sale SEE REMARKS sold 2,446 shares at $7.63 ($18,663)
- 4 Open-market sale CHIEF EXECUTIVE OFFICER sold 5,779 shares at $7.63 ($44,094)
Page 2 of 15 · 288 filings